|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2006
|
|
gptkbp:ATCCode
|
gptkb:L01XE04
|
|
gptkbp:brand
|
gptkb:Sutent
|
|
gptkbp:CASNumber
|
gptkb:557795-19-4
|
|
gptkbp:chemicalClass
|
indolinone
|
|
gptkbp:color
|
yellow powder
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Sugen
|
|
gptkbp:eliminationHalfLife
|
40-60 hours
|
|
gptkbp:hasActiveMetabolite
|
SU12662
|
|
gptkbp:hasMolecularFormula
|
C22H27FN4O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sunitinib
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
patent expired in US (2021)
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
|
|
gptkbp:MeSH_ID
|
C522097
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
5329102
CHEMBL535
DB01268
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
vomiting
diarrhea
anorexia
fatigue
hypertension
rash
mucositis
|
|
gptkbp:solubility
|
sparingly soluble in water
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
UH2A2J35Y7
|
|
gptkbp:usedFor
|
gptkb:gastrointestinal_stromal_tumor
gptkb:pancreatic_neuroendocrine_tumors
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:PDGFR
gptkb:PDGFRB
gptkb:CYP3A5
gptkb:VEGFR2
gptkb:VEGF_signaling_pathway
gptkb:CYP3A4_gene
gptkb:KDR
gptkb:Platelet-derived_growth_factor
gptkb:PDGFRα
|
|
gptkbp:bfsLayer
|
6
|